Darong Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Darong Yang has a total of 132 co-authors. Here are the top co-authors by number of shared publications:
- Haizhen Zhu
Institute of Pathogen Biology and Immunology, College of Biology, State Key Laboratory of Chemo/Biosensing and Chemometrics, Hunan University, Changsha, China
16 shared publications Xiaohong Wang
Department of Molecular Medicine, College of Biology, State Key Laboratory of Chemo/Biosensing and Chemometrics, Hunan University, Changsha 410082, Hunan, China
16 shared publicationsNianli Liu
Department of Molecular Medicine, College of Biology, State Key Laboratory of Chemo / Biosensing and Chemometrics, Hunan University, No 2 Lushan South Road, Changsha, 410082, China
13 shared publicationsBinbin Xue
Institute of Pathogen Biology and Immunology of College of Biology, State Key Laboratory of Chemo/Biosensing and Chemometrics, Hunan University, Changsha, Hunan, China
10 shared publicationsHaizhen Zhu
Department of Molecular Medicine of College of Biology, State Key Laboratory of Chemo/Biosensing and Chemometrics, Hunan University, Changsha, China Research Center of Cancer Prevention and Treatment, Translational Medicine Research Center of Liver Cancer, Hunan Provincial Tumor Hospital (Affiliated Tumor Hospital of Xiangya Medical School of Central South University), Changsha, 410022, China
7 shared publicationsChaohui Zuo
Department of Gastroduodenal and Pancreatic Surgery, Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, Hunan, China
5 shared publications
Latest Publications
- Open Access
TRIM56 Promotes Antiviral Responses Downstream of TLR4
The ubiquitin ligase protein tripartite-motif containing 56 (TRIM56) positively regulates Toll-like receptor-3 (TLR3) signaling by forming a complex with Toll-Interleukin-1 receptor domain-containing adapter protein inducing interferon (IFN)-beta (TRIF), independent of its E3 ligase activity. Whether TRIM56 modulates other TLR pathways in innate antiviral immunity, however, is unclear. Herein, we show ectopic expression of TRIM56 augments activation of IFN regulatory factor-3 (IRF3)-dependent promoters following stimulation by lipopolysaccharide (LPS) in HEK293-TLR4-MD2-CD14 cells while leaving activation of NF-κB-dependent promoter unaffected, suggesting TRIM56 specifically promotes immune signaling through the TLR4-TRIF axis but not the MYD88 arm downstream of this TLR. Confirming its impact on endogenous antiviral responses in immune sentinel cells naturally harboring the TLR4 pathway, we demonstrated enforced expression of TRIM56 enhanced LPS-induced expression of IFN-beta and IFN-stimulated genes (ISGs) and establishment of an antiviral state in bone marrow-derived macrophages. Importantly, depletion of endogenous TRIM56 impaired LPS-induced antiviral gene expression and cellular antiviral defense. Altogether, these data add to understanding of the role of TRIM56 in TLR-mediated innate immune responses. Given that TRIM56 is an ISG and that many immune adjuvants and some viral proteins activate TLR4, the findings of this study could have implications for designing immunotherapies, especially those against viral infections.
Open AccessTRIM56 Promotes Antiviral Responses Downstream of TLR4
The ubiquitin ligase protein tripartite-motif containing 56 (TRIM56) positively regulates Toll-like receptor-3 (TLR3) signaling by forming a complex with Toll-Interleukin-1 receptor domain-containing adapter protein inducing interferon (IFN)-beta (TRIF), independent of its E3 ligase activity. Whether TRIM56 modulates other TLR pathways in innate antiviral immunity, however, is unclear. Herein, we show ectopic expression of TRIM56 augments activation of IFN regulatory factor-3 (IRF3)-dependent promoters following stimulation by lipopolysaccharide (LPS) in HEK293-TLR4-MD2-CD14 cells while leaving activation of NF-κB-dependent promoter unaffected, suggesting TRIM56 specifically promotes immune signaling through the TLR4-TRIF axis but not the MYD88 arm downstream of this TLR. Confirming its impact on endogenous antiviral responses in immune sentinel cells naturally harboring the TLR4 pathway, we demonstrated enforced expression of TRIM56 enhanced LPS-induced expression of IFN-beta and IFN-stimulated genes (ISGs) and establishment of an antiviral state in bone marrow-derived macrophages. Importantly, depletion of endogenous TRIM56 impaired LPS-induced antiviral gene expression and cellular antiviral defense. Altogether, these data add to understanding of the role of TRIM56 in TLR-mediated innate immune responses. Given that TRIM56 is an ISG and that many immune adjuvants and some viral proteins activate TLR4, the findings of this study could have implications for designing immunotherapies, especially those against viral infections.
- Open Access
- 19 June 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (25) , eaeh1439
Control of naive T cell reactivity and peripheral tolerance by ascorbate and TET activity
Peripheral tolerance depends on limiting conventional T cell responses to self-antigens. To define the contribution of nutritional factors and related epigenetic regulation, we perform in vivo CRISPR screening and identify the ascorbate transporter Slc23a2 as a key regulator of naive T cell (Tn) reactivity. T cell–specific loss of Slc23a2 reduces intracellular ascorbate, induces regional DNA hypermethylation, enhances differentiation of Tn cells into effector and memory populations, and promotes low-grade autoimmune inflammation. These phenotypes mirror those caused by ascorbate deprivation, TET dioxygenase deficiency, and aging. Mechanistically, Slc23a2 maintains TET enzymatic activity through ascorbate, dampens proximal TCR signaling, represses helper T cell lineage programs, and sustains Tcf1 expression and chromatin binding in Tn cells. Deletion of Tcf7 partially phenocopies Slc23a2 deficiency, whereas Tcf1 overexpression mitigates the effects. Together, these findings identify ascorbate and TET-dependent DNA demethylation as a checkpoint that restrains Tn cell reactivity to self-antigens, thereby maintaining peripheral tolerance, a process compromised with aging.
- 19 June 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (25) , eaeh1439
Open AccessControl of naive T cell reactivity and peripheral tolerance by ascorbate and TET activity
Peripheral tolerance depends on limiting conventional T cell responses to self-antigens. To define the contribution of nutritional factors and related epigenetic regulation, we perform in vivo CRISPR screening and identify the ascorbate transporter Slc23a2 as a key regulator of naive T cell (Tn) reactivity. T cell–specific loss of Slc23a2 reduces intracellular ascorbate, induces regional DNA hypermethylation, enhances differentiation of Tn cells into effector and memory populations, and promotes low-grade autoimmune inflammation. These phenotypes mirror those caused by ascorbate deprivation, TET dioxygenase deficiency, and aging. Mechanistically, Slc23a2 maintains TET enzymatic activity through ascorbate, dampens proximal TCR signaling, represses helper T cell lineage programs, and sustains Tcf1 expression and chromatin binding in Tn cells. Deletion of Tcf7 partially phenocopies Slc23a2 deficiency, whereas Tcf1 overexpression mitigates the effects. Together, these findings identify ascorbate and TET-dependent DNA demethylation as a checkpoint that restrains Tn cell reactivity to self-antigens, thereby maintaining peripheral tolerance, a process compromised with aging.
- 18 December 2025
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 390 (6779) , eadw8310
Conformational landscape adaptations enable processive phosphorylation by Src family kinases
Processive phosphorylation by kinases enables the rapid multisite modification of signaling hubs, serving to integrate signals during time-sensitive cellular events. To achieve processivity, multiple catalytic cycles must occur before substrate dissociation, making rapid turnover rates essential. Src family kinases processively phosphorylate multisite substrates. Using nuclear magnetic resonance spectroscopy, we identified a transient intermediate state within the Src conformational ensemble, positioned between its active and inactive states. This intermediate state facilitates the rapid release of adenosine diphosphate following adenosine triphosphate hydrolysis, ensuring efficient catalytic turnover. Depletion of the intermediate state abrogated processive phosphorylation by Src, Lck, and Hck, impairing function. These findings reveal that the conformational ensemble of Src family kinases has evolved to incorporate a transient state that underpins their capacity for processive substrate phosphorylation.
- 18 December 2025
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 390 (6779) , eadw8310
Conformational landscape adaptations enable processive phosphorylation by Src family kinases
Processive phosphorylation by kinases enables the rapid multisite modification of signaling hubs, serving to integrate signals during time-sensitive cellular events. To achieve processivity, multiple catalytic cycles must occur before substrate dissociation, making rapid turnover rates essential. Src family kinases processively phosphorylate multisite substrates. Using nuclear magnetic resonance spectroscopy, we identified a transient intermediate state within the Src conformational ensemble, positioned between its active and inactive states. This intermediate state facilitates the rapid release of adenosine diphosphate following adenosine triphosphate hydrolysis, ensuring efficient catalytic turnover. Depletion of the intermediate state abrogated processive phosphorylation by Src, Lck, and Hck, impairing function. These findings reveal that the conformational ensemble of Src family kinases has evolved to incorporate a transient state that underpins their capacity for processive substrate phosphorylation.
- 1 July 2019
- Published by Elsevier in Biomaterials
- Vol. 210, 83-93
Plant-derived RNAi therapeutics: A strategic inhibitor of HBsAg
- 1 July 2019
- Published by Elsevier in Biomaterials
- Vol. 210, 83-93
Plant-derived RNAi therapeutics: A strategic inhibitor of HBsAg
- Open Access
- 28 June 2019
- Published by Public Library of Science (PLoS) in PLOS Neglected Tropical Diseases
- Vol. 13 (6) , e0007537
The E3 ligase TRIM56 is a host restriction factor of Zika virus and depends on its RNA-binding activity but not miRNA regulation, for antiviral function
Infection by Zika virus (ZIKV) is linked to microcephaly and other neurological disorders, posing a significant health threat. Innate immunity is the first line of defense against invading pathogens, but relatively little is understood regarding host intrinsic mechanisms that guard against ZIKV. Here, we show that host tripartite motif-containing protein 56 (TRIM56) poses a barrier to ZIKV infection in cells of neural, epithelial and fibroblast origins. Overexpression of TRIM56, but not an E3 ligase-dead mutant or one lacking a short C-terminal portion, inhibited ZIKV RNA replication. Conversely, depletion of TRIM56 increased viral RNA levels. Although the C-terminal region of TRIM56 bears sequence homology to NHL repeat of TRIM-NHL proteins that regulate miRNA activity, knockout of Dicer, which abolishes production of miRNAs, had no demonstrable effect on ZIKV restriction imposed by TRIM56. Rather, we found that TRIM56 is an RNA-binding protein that associates with ZIKV RNA in infected cells. Moreover, a recombinant TRIM56 fragment comprising the C-terminal 392 residues captured ZIKV RNA in cell-free reactions, indicative of direct interaction. Remarkably, deletion of a short C-terminal tail portion abrogated the TRIM56-ZIKV RNA interaction, concomitant with a loss in antiviral activity. Altogether, our study reveals TRIM56 is an RNA binding protein that acts as a ZIKV restriction factor and provides new insights into the antiviral mechanism by which this E3 ligase tackles flavivirus infections. The E3 ligase TRIM56 was previously shown to inhibit the replication of several viruses in the family Flaviviridae, including dengue virus serotype 2, yellow fever virus and bovine viral diarrhea virus, but had not demonstrable antiviral effect against hepatitis C virus, a hepatotropic virus in the same family. Nonetheless, the antiviral mechanism remains unclear and whether TRIM56 restricts other flaviviruses remains to be determined. In this study we demonstrated that TRIM56 inhibits ZIKVs of Asian and African lineages and a dengue virus serotype 1 replicon. We additionally uncovered that TRIM56 is an RNA-binding protein and that a portion of the C-terminal NHL-like domain mediates the association of TRIM56 with ZIKV RNAs in infected cells. Importantly, the RNA-binding activity of TRIM56 was found to be required for its antiviral function, although it alone is insufficient. In contrast, TRIM56 restricted ZIKV in Dicer-deficient cells, indicating an antiviral mechanism independent of miRNA regulation, a function known to be associated with NHL-containing proteins. In aggregate, our work identifies TRIM56 as a novel restriction factor of ZIKV and sheds new lights on the antiviral mechanism of TRIM56 against flaviviruses.
- 28 June 2019
- Published by Public Library of Science (PLoS) in PLOS Neglected Tropical Diseases
- Vol. 13 (6) , e0007537
Open AccessThe E3 ligase TRIM56 is a host restriction factor of Zika virus and depends on its RNA-binding activity but not miRNA regulation, for antiviral function
Infection by Zika virus (ZIKV) is linked to microcephaly and other neurological disorders, posing a significant health threat. Innate immunity is the first line of defense against invading pathogens, but relatively little is understood regarding host intrinsic mechanisms that guard against ZIKV. Here, we show that host tripartite motif-containing protein 56 (TRIM56) poses a barrier to ZIKV infection in cells of neural, epithelial and fibroblast origins. Overexpression of TRIM56, but not an E3 ligase-dead mutant or one lacking a short C-terminal portion, inhibited ZIKV RNA replication. Conversely, depletion of TRIM56 increased viral RNA levels. Although the C-terminal region of TRIM56 bears sequence homology to NHL repeat of TRIM-NHL proteins that regulate miRNA activity, knockout of Dicer, which abolishes production of miRNAs, had no demonstrable effect on ZIKV restriction imposed by TRIM56. Rather, we found that TRIM56 is an RNA-binding protein that associates with ZIKV RNA in infected cells. Moreover, a recombinant TRIM56 fragment comprising the C-terminal 392 residues captured ZIKV RNA in cell-free reactions, indicative of direct interaction. Remarkably, deletion of a short C-terminal tail portion abrogated the TRIM56-ZIKV RNA interaction, concomitant with a loss in antiviral activity. Altogether, our study reveals TRIM56 is an RNA binding protein that acts as a ZIKV restriction factor and provides new insights into the antiviral mechanism by which this E3 ligase tackles flavivirus infections. The E3 ligase TRIM56 was previously shown to inhibit the replication of several viruses in the family Flaviviridae, including dengue virus serotype 2, yellow fever virus and bovine viral diarrhea virus, but had not demonstrable antiviral effect against hepatitis C virus, a hepatotropic virus in the same family. Nonetheless, the antiviral mechanism remains unclear and whether TRIM56 restricts other flaviviruses remains to be determined. In this study we demonstrated that TRIM56 inhibits ZIKVs of Asian and African lineages and a dengue virus serotype 1 replicon. We additionally uncovered that TRIM56 is an RNA-binding protein and that a portion of the C-terminal NHL-like domain mediates the association of TRIM56 with ZIKV RNAs in infected cells. Importantly, the RNA-binding activity of TRIM56 was found to be required for its antiviral function, although it alone is insufficient. In contrast, TRIM56 restricted ZIKV in Dicer-deficient cells, indicating an antiviral mechanism independent of miRNA regulation, a function known to be associated with NHL-containing proteins. In aggregate, our work identifies TRIM56 as a novel restriction factor of ZIKV and sheds new lights on the antiviral mechanism of TRIM56 against flaviviruses.
- Open Access
- 19 June 2018
- Published by SAGE Publications in Cancer Biomarkers
- Vol. 22 (3) , 453-466
miR-370 regulates ISG15 expression and influences IFN-α sensitivity in hepatocellular carcinoma cells
BACKGROUND: Interferon-α (IFN-α ) is an adjuvant to chemotherapy and radiotherapy for hepatocellular carcinoma (HCC), but some HCC patients do not respond to treatment with IFN-α . METHODS: We performed loss-of-function and gain-of-function experimen
- 19 June 2018
- Published by SAGE Publications in Cancer Biomarkers
- Vol. 22 (3) , 453-466
Open AccessmiR-370 regulates ISG15 expression and influences IFN-α sensitivity in hepatocellular carcinoma cells
BACKGROUND: Interferon-α (IFN-α ) is an adjuvant to chemotherapy and radiotherapy for hepatocellular carcinoma (HCC), but some HCC patients do not respond to treatment with IFN-α . METHODS: We performed loss-of-function and gain-of-function experimen
- 1 April 2018
- Published by Elsevier in Pancreatology
- Vol. 18 (3) , 328-333
Celecoxib suppresses proliferation and metastasis of pancreatic cancer cells by down-regulating STAT3 / NF-kB and L1CAM activities
- 1 April 2018
- Published by Elsevier in Pancreatology
- Vol. 18 (3) , 328-333
Celecoxib suppresses proliferation and metastasis of pancreatic cancer cells by down-regulating STAT3 / NF-kB and L1CAM activities
- 1 December 2017
- Published by American Society for Microbiology in Journal of Virology
- Vol. 91 (23) , e01264-17
NLRX1 Mediates MAVS Degradation To Attenuate the Hepatitis C Virus-Induced Innate Immune Response through PCBP2
Activation of innate immunity is essential for host cells to restrict the spread of invading viruses and other pathogens. However, attenuation or termination of signaling is also necessary for preventing immune-mediated tissue damage and spontaneous autoimmunity. Here, we identify nucleotide binding oligomerization domain (NOD)-like receptor X1 (NLRX1) as a negative regulator of the mitochondrial antiviral signaling protein (MAVS)-mediated signaling pathway during hepatitis C virus (HCV) infection. The depletion of NLRX1 enhances the HCV-triggered activation of interferon (IFN) signaling and causes the suppression of HCV propagation in hepatocytes. NLRX1, a HCV-inducible protein, interacts with MAVS and mediates the K48-linked polyubiquitination and subsequent degradation of MAVS via the proteasomal pathway. Moreover, poly(rC) binding protein 2 (PCBP2) interacts with NLRX1 to participate in the NLRX1-induced degradation of MAVS and the inhibition of antiviral responses during HCV infection. Mutagenic analyses further revealed that the NOD of NLRX1 is essential for NLRX1 to interact with PCBP2 and subsequently induce MAVS degradation. Our study unlocks a key mechanism of the fine-tuning of innate immunity by which NLRX1 restrains the retinoic acid-inducible gene I-like receptor (RLR)-MAVS signaling cascade by recruiting PCBP2 to MAVS for inducing MAVS degradation through the proteasomal pathway. NLRX1, a negative regulator of innate immunity, is a pivotal host factor for HCV to establish persistent infection. IMPORTANCE Innate immunity needs to be tightly regulated to maximize the antiviral response and minimize immune-mediated pathology, but the underlying mechanisms are poorly understood. In this study, we report that NLRX1 is a proviral host factor for HCV infection and functions as a negative regulator of the HCV-triggered innate immune response. NLRX1 recruits PCBP2 to MAVS and induces the K48-linked polyubiquitination and degradation of MAVS, leading to the negative regulation of the IFN signaling pathway and promoting HCV infection. Overall, this study provides intriguing insights into how innate immunity is regulated during viral infection.
- 1 December 2017
- Published by American Society for Microbiology in Journal of Virology
- Vol. 91 (23) , e01264-17
NLRX1 Mediates MAVS Degradation To Attenuate the Hepatitis C Virus-Induced Innate Immune Response through PCBP2
Activation of innate immunity is essential for host cells to restrict the spread of invading viruses and other pathogens. However, attenuation or termination of signaling is also necessary for preventing immune-mediated tissue damage and spontaneous autoimmunity. Here, we identify nucleotide binding oligomerization domain (NOD)-like receptor X1 (NLRX1) as a negative regulator of the mitochondrial antiviral signaling protein (MAVS)-mediated signaling pathway during hepatitis C virus (HCV) infection. The depletion of NLRX1 enhances the HCV-triggered activation of interferon (IFN) signaling and causes the suppression of HCV propagation in hepatocytes. NLRX1, a HCV-inducible protein, interacts with MAVS and mediates the K48-linked polyubiquitination and subsequent degradation of MAVS via the proteasomal pathway. Moreover, poly(rC) binding protein 2 (PCBP2) interacts with NLRX1 to participate in the NLRX1-induced degradation of MAVS and the inhibition of antiviral responses during HCV infection. Mutagenic analyses further revealed that the NOD of NLRX1 is essential for NLRX1 to interact with PCBP2 and subsequently induce MAVS degradation. Our study unlocks a key mechanism of the fine-tuning of innate immunity by which NLRX1 restrains the retinoic acid-inducible gene I-like receptor (RLR)-MAVS signaling cascade by recruiting PCBP2 to MAVS for inducing MAVS degradation through the proteasomal pathway. NLRX1, a negative regulator of innate immunity, is a pivotal host factor for HCV to establish persistent infection. IMPORTANCE Innate immunity needs to be tightly regulated to maximize the antiviral response and minimize immune-mediated pathology, but the underlying mechanisms are poorly understood. In this study, we report that NLRX1 is a proviral host factor for HCV infection and functions as a negative regulator of the HCV-triggered innate immune response. NLRX1 recruits PCBP2 to MAVS and induces the K48-linked polyubiquitination and degradation of MAVS, leading to the negative regulation of the IFN signaling pathway and promoting HCV infection. Overall, this study provides intriguing insights into how innate immunity is regulated during viral infection.
- Open Access
- 30 October 2017
- Published by Public Library of Science (PLoS) in PLOS Pathogens
- Vol. 13 (10) , e1006713
Pivotal role for the ESCRT-II complex subunit EAP30/SNF8 in IRF3-dependent innate antiviral defense
The activation of interferon (IFN)-regulatory factor-3 (IRF3), characterized by phosphorylation and nuclear translocation of the latent transcription factor, is central to initiating innate antiviral responses. Whereas much has been learned about the upstream pathways and signaling mechanisms leading to IRF3 activation, how activated IRF3 operates in the nucleus to control transcription of IFNs remains obscure. Here we identify EAP30 (a.k.a, SNF8/VPS22), an endosomal sorting complex required for transport (ESCRT)-II subunit, as an essential factor controlling IRF3-dependent antiviral defense. Depletion of EAP30, but not other ESCRT-II subunits, compromised IRF3-dependent induction of type I and III IFNs, IFN-stimulated genes (ISGs) and chemokines by double-stranded RNA or viruses. EAP30, however, was dispensable for the induction of inflammatory mediators of strict NF-κB target. Significantly, knockdown of EAP30 also impaired the establishment of an antiviral state against vesicular stomatitis virus and hepatitis C virus, which are of distinct viral families. Mechanistically, EAP30 was not required for IRF3 activation but rather acted at a downstream step. Specifically, a fraction of EAP30 localized within the nucleus, where it formed a complex with IRF3 and its transcriptional co-activator, CREB-binding protein (CBP), in a virus-inducible manner. These interactions promoted IRF3 binding to target gene promoters such as IFN-β, IFN-λ1 and ISG56. Together, our data describe an unappreciated role for EAP30 in IRF3-dependent innate antiviral response in the nucleus. The induction of IFN antiviral response is a hallmark of immediate host immune responses to viral infections. In a majority of cell types, eliciting this intrinsic defense mechanism depends on activation of IRF3, characterized by C-terminal phosphorylation, dimerization and subsequent nuclear translocation of the latent transcription factor. While the molecular pathways and signaling events leading to IRF3 activation have been extensively studied, how activated IRF3 operates in the nucleus to trigger antiviral gene expression remains murky. In this study, we reveal that EAP30, an endosomal sorting complex required for transport (ESCRT)-II subunit, is a novel, pivotal factor controlling IRF3-dependent antiviral defense. We demonstrate that a fraction of EAP30 resides in the nucleus, where it forms a complex with IRF3 and its transcriptional co-activator, CBP, in response to viral insults. These interactions are essential for IRF3 binding to its target gene promoters and subsequent transcription of antiviral genes including those encoding type I and III IFNs and IFN-stimulated genes. Our data unveil a previously unappreciated role for EAP30 in facilitating IRF3-mediated antiviral response in the nucleus and raise the possibility that this novel function of EAP30 may be targeted for developing antiviral interventions to combat infectious diseases.
- 30 October 2017
- Published by Public Library of Science (PLoS) in PLOS Pathogens
- Vol. 13 (10) , e1006713
Open AccessPivotal role for the ESCRT-II complex subunit EAP30/SNF8 in IRF3-dependent innate antiviral defense
The activation of interferon (IFN)-regulatory factor-3 (IRF3), characterized by phosphorylation and nuclear translocation of the latent transcription factor, is central to initiating innate antiviral responses. Whereas much has been learned about the upstream pathways and signaling mechanisms leading to IRF3 activation, how activated IRF3 operates in the nucleus to control transcription of IFNs remains obscure. Here we identify EAP30 (a.k.a, SNF8/VPS22), an endosomal sorting complex required for transport (ESCRT)-II subunit, as an essential factor controlling IRF3-dependent antiviral defense. Depletion of EAP30, but not other ESCRT-II subunits, compromised IRF3-dependent induction of type I and III IFNs, IFN-stimulated genes (ISGs) and chemokines by double-stranded RNA or viruses. EAP30, however, was dispensable for the induction of inflammatory mediators of strict NF-κB target. Significantly, knockdown of EAP30 also impaired the establishment of an antiviral state against vesicular stomatitis virus and hepatitis C virus, which are of distinct viral families. Mechanistically, EAP30 was not required for IRF3 activation but rather acted at a downstream step. Specifically, a fraction of EAP30 localized within the nucleus, where it formed a complex with IRF3 and its transcriptional co-activator, CREB-binding protein (CBP), in a virus-inducible manner. These interactions promoted IRF3 binding to target gene promoters such as IFN-β, IFN-λ1 and ISG56. Together, our data describe an unappreciated role for EAP30 in IRF3-dependent innate antiviral response in the nucleus. The induction of IFN antiviral response is a hallmark of immediate host immune responses to viral infections. In a majority of cell types, eliciting this intrinsic defense mechanism depends on activation of IRF3, characterized by C-terminal phosphorylation, dimerization and subsequent nuclear translocation of the latent transcription factor. While the molecular pathways and signaling events leading to IRF3 activation have been extensively studied, how activated IRF3 operates in the nucleus to trigger antiviral gene expression remains murky. In this study, we reveal that EAP30, an endosomal sorting complex required for transport (ESCRT)-II subunit, is a novel, pivotal factor controlling IRF3-dependent antiviral defense. We demonstrate that a fraction of EAP30 resides in the nucleus, where it forms a complex with IRF3 and its transcriptional co-activator, CBP, in response to viral insults. These interactions are essential for IRF3 binding to its target gene promoters and subsequent transcription of antiviral genes including those encoding type I and III IFNs and IFN-stimulated genes. Our data unveil a previously unappreciated role for EAP30 in facilitating IRF3-mediated antiviral response in the nucleus and raise the possibility that this novel function of EAP30 may be targeted for developing antiviral interventions to combat infectious diseases.